ARO ALK7
Alternative Names: ARO-ALK7Latest Information Update: 09 Dec 2024
Price :
$50 *
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Obesity therapies; Small interfering RNA
- Mechanism of Action ACVR1C protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 03 Dec 2024 Arrowhead Pharmaceuticals requests a regulatory clearance to initiate phase I/IIa trial in Obesity
- 03 Dec 2024 Arrowhead Pharmaceuticals plans a phase I/IIa trial in Obesity (In volunteers) in early 2025
- 20 Aug 2024 Arrowhead Pharmaceuticals announces intention to submit clinical trial applications with regulatory authorities for Obesity and Metabolic disorders in late 2024